Clinical Trial Update: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study of DS-1594b with or without azacitidine, venetoclax, or mini-HCVD in relapsed or refractory acute myeloid leukemia or acute lymphoblastic leuk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• DS-1594b
• Mini-HCVD
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-05-23